...
首页> 外文期刊>Intensive care medicine >Pretreatment with peroxysome proliferator-activated receptor alpha agonist fenofibrate protects endothelium in rabbit Escherichia coli endotoxin-induced shock.
【24h】

Pretreatment with peroxysome proliferator-activated receptor alpha agonist fenofibrate protects endothelium in rabbit Escherichia coli endotoxin-induced shock.

机译:用过氧化物酶体增殖物激活的受体α激动剂非诺贝特预处理可保护兔大肠杆菌内毒素诱导的休克中的内皮。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE: To investigate the effects of fenofibrate, an activator of peroxysome proliferator activated receptor (PPAR) alpha, on vascular endothelium and on hemostasis in a rabbit endotoxic shock model. DESIGN AND SETTING: Prospective laboratory study in a university laboratory. SUBJECTS: 36 male New Zealand rabbits weighing 2.5-3 kg. INTERVENTIONS: We determined in vitro vascular reactivity, endothelium CD31-platelet/endothelial cell adhesion molecule (PECAM) 1 immunohistochemistry, plasma coagulation factors, and monocyte tissue factor expression 5 days after onset of endotoxic shock (0.5 mg/kg intravenous bolus, Escherichia coli lipopolysaccharide) with or without treatment by fenofibrate (mixed in the chow at a concentration of 0.5%) for 15 days before lipopolysaccharide injection and 5 days afterward. MEASUREMENTS AND RESULTS: Metabolic acidosis and coagulation activation confirmed presence of shock. Fenofibrate decreased monocyte tissue factor expression. It improved endothelial-dependent relaxation at 5 days (Emax=68.2+/-3.3%, vs. 44.2+/-2.5% in the non-treated group). Endotoxin-induced deendothelialization was significantly decreased by fenofibrate at 5 days (8.5+/-1.3% vs. 19.2+/-3.1% in the nontreated group) .CONCLUSIONS: These data indicate for the first time that fenofibrate, an activator of PPAR-alpha, inhibits monocyte tissue factor expression and protects against endothelial dysfunction and histological injury in endotoxin-induced shock.
机译:目的:研究非诺贝特(一种过氧化物酶体增殖物激活受体(PPAR)α的激活剂)对兔内毒素休克模型中血管内皮和止血的影响。设计与设置:在大学实验室进行前瞻性实验室研究。受试者:36只雄性新西兰兔,体重2.5-3公斤。干预:我们在发生内毒素性休克(0.5 mg / kg静脉推注)后5天,测定了体外血管反应性,内皮CD31-血小板/内皮细胞粘附分子(PECAM)1的免疫组织化学,血浆凝血因子和单核细胞组织因子的表达。注射非多糖前15天和注射后5天,是否接受非诺贝特治疗(以0.5%的浓度混合在食物中)。测量和结果:代谢性酸中毒和凝血激活证实存在休克。非诺贝特降低单核细胞组织因子表达。它改善了5天的内皮依赖性舒张功能(Emax = 68.2 +/- 3.3%,而未治疗组为44.2 +/- 2.5%)。非诺贝特在5天时内毒素诱导的去内皮化显着降低(8.5 +/- 1.3%比未治疗组的19.2 +/- 3.1%)。结论:这些数据首次表明非诺贝特是PPAR-激活剂α,抑制单核细胞组织因子的表达,并防止内毒素引起的休克中的内皮功能障碍和组织学损伤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号